Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
Publication
, Journal Article
Cox, ME; Rowell, J; Corsino, L; Green, JB
Published in: Drug Healthc Patient Saf
2010
Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 diabetes, which has become widely incorporated into clinical practice. This review summarizes the available data on the efficacy, safety, and tolerability of these medications.
Duke Scholars
Published In
Drug Healthc Patient Saf
DOI
EISSN
1179-1365
Publication Date
2010
Volume
2
Start / End Page
7 / 19
Location
New Zealand
Related Subject Headings
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Cox, M. E., Rowell, J., Corsino, L., & Green, J. B. (2010). Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf, 2, 7–19. https://doi.org/10.2147/dhps.s6270
Cox, Mary Elizabeth, Jennifer Rowell, Leonor Corsino, and Jennifer B. Green. “Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.” Drug Healthc Patient Saf 2 (2010): 7–19. https://doi.org/10.2147/dhps.s6270.
Cox ME, Rowell J, Corsino L, Green JB. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf. 2010;2:7–19.
Cox, Mary Elizabeth, et al. “Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.” Drug Healthc Patient Saf, vol. 2, 2010, pp. 7–19. Pubmed, doi:10.2147/dhps.s6270.
Cox ME, Rowell J, Corsino L, Green JB. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf. 2010;2:7–19.
Published In
Drug Healthc Patient Saf
DOI
EISSN
1179-1365
Publication Date
2010
Volume
2
Start / End Page
7 / 19
Location
New Zealand
Related Subject Headings
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences